Imugene Limited Initiates Phase 1 onCARlytics CD19 Virus Clinical Trial.

Imugene Limited (ASX: IMU), a pioneer in immuno-oncology, has marked a significant milestone as it initiates the Phase 1 clinical trial for onCARlytics, their CD19 oncolytic virotherapy candidate. This groundbreaking trial, known as OASIS, is the first of its kind, combining a CD19 oncolytic virus with a CD19 drug. The trial targets patients with solid tumors, specifically focusing on those with advanced or metastatic solid tumors.

OnCARlytics, when combined with the CD19-targeting bispecific monoclonal antibody blinatumomab (Amgen's Blincyto®), has the potential to revolutionize the treatment of solid tumors that were previously untreatable with Blincyto® alone. The study involves assessing the safety and efficacy of two administration routes: intratumoral (IT) injection and intravenous (IV) infusion, both as standalone treatments and in conjunction with blinatumomab. This Phase 1 trial is being conducted in the United States and represents a pivotal step in the field of immuno-oncology. The initial dosing of the first patient, who has ovarian cancer, took place at the renowned City of Hope's NCI-Designated Comprehensive Cancer Center in Duarte, California, USA.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com